A. Moses

发表

Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate.

Stephanie L. Lee, J. Garber, H. Rosen, 1998, The Journal of clinical endocrinology and metabolism.

Recombinant Human Insulin-Like Growth Factor I Increases Insulin Sensitivity and Improves Glycemic Control in Type II Diabetes

A. Moses, D. Clemmons, S. Young, 1996, Diabetes.

Distribution and characterization of insulin and insulin-like growth factor I receptors in normal human ovary.

F. Grigorescu, A. Moses, L. Poretsky, 1985, The Journal of clinical endocrinology and metabolism.

LEADER 3—Lipase and Amy lase Activity in Subjects With Type 2 Diabetes Baseline Data From Over 9000 Subjects in the LEADER Trial

B. Zinman, R. Bergenstal, J. Buse, 2014 .

LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes

B. Zinman, R. Bergenstal, J. Buse, 2014, Pancreas.

Differentiation-dependent phosphorylation of a 175,000 molecular weight protein in response to insulin and insulin-like growth factor-I in L6 skeletal muscle cells.

C. Kahn, M. White, A. Moses, 1989, Endocrinology.

Phosphorylation of insulin-like growth factor I receptor by insulin receptor tyrosine kinase in intact cultured skeletal muscle cells.

C. Kahn, M. White, A. Moses, 1988, Biochemistry.

Treatment with growth hormone and IGF‐I in growing rats increases bone mineral content but not bone mineral density

P. Douglas, H. Rosen, A. Moses, 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Insulin-like growth factor I in human thyroid tissue: Specific localization by immunohistochemistry andIn Situ hybridization

A. Moses, E. Kimura, R. Maciel, 1995 .

Characterization of the receptors for insulin and the insulin-like growth factors on micro- and macrovascular tissues.

C. Kahn, S. Buzney, G. King, 1985, Endocrinology.

Serum CTX: A New Marker of Bone Resorption That Shows Treatment Effect More Often Than Other Markers Because of Low Coefficient of Variability and Large Changes with Bisphosphonate Therapy

H. Rosen, A. Moses, J. Garber, 2000, Calcified Tissue International.

Insulin stimulation of aminoisobutyric acid transport in human skin fibroblasts is mediated through both insulin and type I insulin-like growth factor receptors.

P. Usher, A. Moses, J. Flier, 1986, The Journal of clinical endocrinology and metabolism.

Monoclonal antibody to the type I insulin-like growth factor (IGF-I) receptor blocks IGF-I receptor-mediated DNA synthesis: clarification of the mitogenic mechanisms of IGF-I and insulin in human skin fibroblasts.

P. Usher, A. Moses, J. Flier, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Developmental expression of receptors for insulin, insulin-like growth factor I (IGF-I), and IGF-II in rat skeletal muscle.

T. Alexandrides, A. Moses, R. Smith, 1989, Endocrinology.

Beta-cell insulin secretory response to oral hypoglycemic agents is blunted in humans in vivo during moderate hypoglycemia.

A. Goldfine, A. Moses, R. Carr, 2004, The Journal of clinical endocrinology and metabolism.

The development of insulin receptors and responsiveness is an early marker of differentiation in the muscle cell line L6.

C. Kahn, A. Moses, F. Beguinot, 1986, Endocrinology.

Insulin resistance and type 2 diabetes mellitus: is there a therapeutic role for IGF-1?

A. Moses, 2005, Endocrine development.

Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance.

D. Moller, A. Moses, L. Morrow, 1994, The Journal of clinical endocrinology and metabolism.

Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus.

J. Flier, D. Moller, A. Moses, 1995, Diabetes research and clinical practice.

The growth hormone dependence of a somatomedin-binding protein in human serum.

A. Moses, M. Rechler, S. Nissley, 1981, The Journal of clinical endocrinology and metabolism.

Wortmannin-Sensitive Pathway : Studies in Rat and Ferret Isolated Muscles Through a 2 + Myocardial Contractility by Sensitizing the Myofilament to Ca Insulin-like Growth Factor-1 but Not Growth Hormone Augments Mammalian

P. Douglas, J. Ingwall, A. Moses, 1998 .

Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose.

A. Rogol, A. Moses, A. Sommer, 2005, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

Response to Swinnen et al.

A. Moses, C. Koenen, 2010, Diabetes technology & therapeutics.

Developing, Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events)

A. Moses, I. C. Helmark, A. Hvelplund, 2019, Therapeutic innovation & regulatory science.

Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)

B. Zinman, T. Pieber, N. Poulter, 2019, Diabetes, obesity & metabolism.

Does serum 1,5‐anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine

P. Raskin, A. Moses, N. Khutoryansky, 2008, Diabetic medicine : a journal of the British Diabetic Association.

Utility of Biochemical Markers of Bone Turnover in the Follow-up of Patients Treated with Bisphosphonates

H. Rosen, A. Moses, J. Garber, 1998, Calcified Tissue International.

Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta‐analysis of the liraglutide clinical trial programme

S. Gough, B. Zinman, A. Moses, 2012, Diabetes, obesity & metabolism.

Abstracts of lectures symposium disposition and delivery of peptide drugs

H. M. Patel, Kevin R. Smith, V. H. Lee, 1988, Pharmaceutisch Weekblad.

Insulin-mediated pseudoacromegaly: clinical and biochemical characterization of a syndrome of selective insulin resistance.

S. O’Rahilly, J. Flier, F. Grigorescu, 1993, The Journal of clinical endocrinology and metabolism.

Thyroid hormone and growth hormone interact to regulate insulin-like growth factor-I messenger ribonucleic acid and circulating levels in the rat.

A. Moses, S. Ingbar, M. Wolf, 1989, Endocrinology.

GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide.

L. Hegedüs, G. Daniels, A. Moses, 2011, The Journal of clinical endocrinology and metabolism.

Hypoglycemia Associated with Trimethoprim/Sulfamethoxazole Therapy

A. Moses, L. Poretsky, 1984, Diabetes Care.

Surgical cure of prolactinoma reverses abnormal prolactin repsonse to carbidopa/L-dopa.

R. Goodman, A. Moses, M. Molitch, 1982, The Journal of clinical endocrinology and metabolism.

Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol: Effectiveness and Reproducibility in Normal and Diabetic Subjects

J. Flier, A. Moses, M. Carey, 1983, Diabetes.

Thyroxine interactions with transthyretin: a comparison of 10 different naturally occurring human transthyretin variants.

J. Liepnieks, M. Benson, H. Rosen, 1993, The Journal of clinical endocrinology and metabolism.

A point mutation in transthyretin increases affinity for thyroxine and produces euthyroid hyperthyroxinemia.

J. Haddow, J. Liepnieks, M. Benson, 1990, The Journal of clinical investigation.

Multiple factors influence insulin-like growth factor-I binding to human skin fibroblasts.

P. Usher, A. Moses, J. Flier, 1989, Endocrinology.

The binding characteristics and biological effects in FRTL5 cells of placental protein-12, an insulin-like growth factor-binding protein purified from human amniotic fluid.

A. Moses, A. Frauman, S. Tsuzaki, 1989, Endocrinology.

Distinct biologically active receptors for insulin, insulin-like growth factor I, and insulin-like growth factor II in cultured skeletal muscle cells.

C. Kahn, A. Moses, F. Beguinot, 1985, The Journal of biological chemistry.

An autocrine/paracrine role for insulin-like growth factors in the regulation of human placental growth.

H. Munro, A. Moses, M. Fant, 1986, The Journal of clinical endocrinology and metabolism.

Recombinant Human Insulin-like Growth Factor as a Therapeutic Agent for Severe Insulin Resistance and Type Η Diabetes Mellitus

A. Moses, 1997 .

Multiplication stimulating activity (MSA) from the BRL 3A rat liver cell line: relation to human somatomedins and insulin.

G. King, A. Moses, E. Van Obberghen-Schilling, 1981, Journal of supramolecular structure and cellular biochemistry.

Adenosine has divergent effects on deoxyribonucleic acid synthesis in FRTL5 cells: inhibition of thyrotropin-stimulated and potentiation of insulin-like growth factor-I-stimulated thymidine incorporation.

A. Moses, B. Veneziani, D. Tramontano, 1989, Endocrinology.

Interactions of Insulin-Like Growth Factor-I (IGF-I) with Multiple Signal Transduction Pathways in FRTL5 Thyroid Follicular Cells

A. Moses, D. Tramontano, A. Frauman, 1989 .

Specific binding of a somatomedin-like polypeptide in rat serum depends on growth hormone

A. Moses, M. Rechler, S. Nissley, 1976, Nature.

Characterization of a somatomedin (insulin-like growth factor) synthesized by fetal rat liver organ cultures.

L. Phillips, A. Moses, M. Rechler, 1979, The Journal of biological chemistry.

Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.

B. Zinman, S. Pocock, N. Poulter, 2013, American heart journal.

Comment on Andersen et al, Pancreatitis–Diabetes–Pancreatic Cancer

A. Moses, L. B. Knudsen, C. B. Svendsen, 2014, Pancreas.

Recombinant insulinlike growth factor-I as therapy in states of altered carbohydrate homeostasis

A. Moses, 1997 .

4 – Insulin-Like Growth Factors

A. Moses, S. J. Pilistine, 1985 .

Biological activity of nasally administered insulin in normal subjects.

J. Flier, A. Moses, J. Karam, 1990, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

IGF in the Treatment of Diabetes

R. Gabbay, A. Moses, 1999 .

Interactions of insulin-like growth factors I and II and multiplication-stimulating activity with receptors and serum carrier proteins.

A. Moses, M. Rechler, S. Nissley, 1980, Endocrinology.

Immunological cross-reactivity of multiplication-stimulating activity polypeptides.

A. Moses, M. Rechler, S. Nissley, 1980, European journal of biochemistry.

Specific insulin binding sites in human ovary.

J. Flier, A. Moses, L. Poretsky, 1984, The Journal of clinical endocrinology and metabolism.

Characterization of insulin-like growth factor binding to human granulosa cells obtained during in vitro fertilization.

J. Flier, A. Moses, L. Poretsky, 1987, Journal of receptor research.

Demonstration of type I and type II somatomedin receptors on bovine growth plate chondrocytes

H. Mankin, A. Moses, S. Chernausek, 1988, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

Demonstration of the production and physiological role of insulin-like growth factor II in rat thyroid follicular cells in culture.

A. Moses, R. Maciel, D. Tramontano, 1988, The Journal of clinical investigation.

Demonstration that a human hepatoma cell line produces a specific insulin-like growth factor carrier protein.

A. Moses, B. Knowles, D. Aden, 1983, The Journal of clinical endocrinology and metabolism.

Nasal absorption of insulin: enhancement by hydrophobic bile salts.

G. S. Gordon, J. Flier, A. Moses, 1985, Proceedings of the National Academy of Sciences of the United States of America.

Factitious hyperthyroxinemia due to a monoclonal IgA in a case of multiple myeloma.

A. Moses, J. Faix, K. Cissewski, 1993, Clinical chemistry.

due to a Monoclonal IgA in a Case of MultipleMyeloma

A. Moses, J. Faix, K. Cissewski, 1993 .

Familial euthyroid hyperthyroxinemia resulting from increased thyroxine binding to thyroxine-binding prealbumin.

J. Haddow, A. Moses, I. Jackson, 1982, The New England journal of medicine.

Purification and characterization of multiplication-stimulating activity. Insulin-like growth factors purified from rat-liver-cell-conditioned medium.

A. Moses, M. Rechler, S. Nissley, 1980, European journal of biochemistry.

Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves'-IgG.

A. Moses, D. Tramontano, S. Ingbar, 1986, Endocrinology.

Rede ﬁ ning Hypoglycemia in Clinical Trials: Validation of De ﬁ nitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes

E. Seaquist, S. Heller, J. Buse, 2020 .

Proinsulin binds to a growth peptide receptor and stimulates DNA synthesis in chick embryo fibroblasts.

A. Moses, M. Rechler, S. Nissley, 1977, Endocrinology.

Somatostatin inhibits deoxyribonucleic acid synthesis induced by both thyrotropin and insulin-like growth factor-I in FRTL5 cells.

A. Moses, S. Tsuzaki, 1990, Endocrinology.

Thyrotropin and dibutyryl cyclic AMP increase levels of c-myc and c-fos mRNAs in cultured rat thyroid cells.

A. Moses, W. Chin, D. Tramontano, 1986, The Journal of biological chemistry.

Bone density is normal in male rats treated with finasteride.

H. Rosen, A. Moses, S. Greenspan, 1995, Endocrinology.

Comment on: Butler et al. A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 Therapies Safe? Diabetes Care 2013;36:2118–2125

N. Vrang, A. Moses, C. B. Svendsen, 2013, Diabetes Care.

Impaired Response of Serum IGF-I Levels to Puberty in Previously Malnourished Adolescents.

A. Moses, J. Galler, J. Vaitukaitis, 1999, Nutritional neuroscience.

Concentrations of Intact Insulin Concurs With FDA and EMA Standards When Measured by HPLC in Different Parts of the Distribution Cold Chain

A. Moses, A. Toft, M. Hach, 2018, Journal of diabetes science and technology.

Structure and Function of Recombinant Human Transthyretin

M. Benson, H. Rosen, A. Moses, 1991 .

Increased levels of multiplication-stimulating activity, an insulin-like growth factor, in fetal rat serum.

A. Moses, M. Rechler, S. Nissley, 1980, Proceedings of the National Academy of Sciences of the United States of America.

Supranormal stimulation of deoxyribonucleic acid synthesis in FRTL5 cells by serum from patients with untreated acromegaly.

A. Moses, A. Lombardi, R. Maciel, 1988, The Journal of clinical endocrinology and metabolism.

Parenteral pamidronate prevents thyroid hormone‐induced bone loss in rats

H. Rosen, A. Moses, S. Greenspan, 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Subregion analysis of the rat femur: A sensitive indicator of changes in bone density following treatment with thyroid hormone or bisphosphonates

H. Rosen, A. Moses, S. Greenspan, 1994, Calcified Tissue International.

Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover

H. Rosen, A. Moses, S. Greenspan, 2004, Calcified Tissue International.

Short-term hyperthyroidism has no effect on leptin levels in man.

C. Mantzoros, H. Rosen, A. Moses, 1997, The Journal of clinical endocrinology and metabolism.

Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans.

M. Holick, H. Rosen, A. Moses, 1993, The Journal of clinical endocrinology and metabolism.

The role of adenosine 3',5'-monophosphate in the regulation of receptors for thyrotropin and insulin-like growth factor I in the FRTL5 rat thyroid follicular cell.

A. Moses, D. Tramontano, S. Ingbar, 1988, Endocrinology.

Adenosine 3',5'-monophosphate mediates both the mitogenic effect of thyrotropin and its ability to amplify the response to insulin-like growth factor I in FRTL5 cells.

A. Moses, B. Veneziani, D. Tramontano, 1988, Endocrinology.

Characterization and regulations of the receptor for insulin-like growth factor-I in the FRTL-5 rat thyroid follicular cell line.

A. Moses, D. Tramontano, S. Ingbar, 1987, Endocrinology.

Regulation of Growth of Thyroid Cells in Culture by TSH Receptor Antibodies and Other Humoral Factors

A. Moses, F. Beguinot, D. Tramontano, 1987 .

Contribution of human somatomedin activity to the serum growth requirement of human skin fibroblasts and chick embryo fibroblasts in culture.

A. Moses, S. Nissley, R. Johnsonbaugh, 1978, The Journal of clinical endocrinology and metabolism.

Whither Recombinant Human Growth Hormone?

C. Mantzoros, A. Moses, 1996, Annals of Internal Medicine.

Evidence that receptor aggregation may play a role in transmembrane signaling through the insulin-like growth factor-I receptor.

A. Moses, J. Flier, H. Yoshino, 1988, Molecular endocrinology.

Characterization of monoclonal antibodies to the IGF-I receptor that inhibit IGF-I binding to human cells.

A. Moses, J. Flier, 1985, Biochemical and biophysical research communications.

Insulin-like growth factor receptors in rat placental membranes.

H. Munro, A. Moses, S. J. Pilistine, 1984, Endocrinology.

Purified human somatomedin A and rat multiplication stimulating activity. Mitogens for cultured fibroblasts that cross-react with the same growth peptide receptors.

A. Moses, M. Rechler, S. Nissley, 1978, European journal of biochemistry.

Identification of a receptor for somatomedin-like polypeptides in human fibroblasts.

A. Moses, M. Rechler, S. Nissley, 1977, The Journal of clinical endocrinology and metabolism.

Further characterization of growth hormone-dependent somatomedin-binding proteins in rat serum and demonstration of somatomedin-binding proteins produced by rat liver cells in culture.

A. Moses, S. Nissley, J. Passamani, 1979, Endocrinology.

Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation.

P. Douglas, A. Moses, R. Clark, 1996, Circulation.

Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial.

C. Mantzoros, S. Gautam, A. Moses, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Local Reaction Secondary to Insulin Injection: A potential role for latex antigens in insulin vials and syringes

A. Moses, F. Twarog, Alison Towse, 1995, Diabetes Care.

Abstracts of Dutch doctoral theses

R. A. Zeeuw, G. J. Jong, M. J. M. Zeeland, 2005, Pharmaceutisch Weekblad.

The A1 adenosine receptor antagonist 1,3, dipropyl-8-cyclopentylxanthine (DPCPX) displays adenosine agonist properties in the FRTL5 thyroid cell line.

A. Moses, A. Frauman, 1989, Biochemical and biophysical research communications.

Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles.

P. Douglas, J. Ingwall, A. Moses, 1998, Circulation research.

Isolated combined growth hormone and gonadotrophin deficiency due to hypothalamic dysfunction, associated with insulin resistance

A. Moses, Chrlstos S. Mantzoros, 1995, Clinical endocrinology.

Circulating insulin concentrations, smoking, and alcohol intake are important independent predictors of leptin in young healthy men.

C. Mantzoros, J. Flier, I. Griveas, 1998, Obesity research.

The interaction of signal transduction pathways in FRTL5 thyroid follicular cells: studies with stable expression of beta 2-adrenergic receptors.

R. Cone, A. Moses, S. Tsuzaki, 1991, Endocrinology.

Placental lactogen administration reverses the effect of low-protein diet on maternal and fetal serum somatomedin levels in the pregnant rat.

H. Munro, A. Moses, S. J. Pilistine, 1984, Proceedings of the National Academy of Sciences of the United States of America.

Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta.

C. Kahn, S. Buzney, G. King, 1985, The Journal of clinical investigation.

Production of insulin-like growth factor binding protein(s) (IGF-BPs) by human placenta: variation with gestational age.

H. Munro, A. Moses, M. Fant, 1988, Placenta.

Production and functional analysis of normal and variant recombinant human transthyretin proteins.

J. Liepnieks, M. Benson, H. Rosen, 1992, The Journal of biological chemistry.

The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity.

A. Moses, A. Sommer, D. Clemmons, 2000, The Journal of clinical endocrinology and metabolism.

Effects of sodium taurodihydrofusidate on nasal absorption of insulin in sheep.

J. Flier, A. Moses, E. Dubovi, 1987, Journal of pharmaceutical sciences.

Empowering People with Diabetes: Improving Perceptions and Outcomes with Technical Advances in Insulin Pens

A. Moses, D. Oyer, M. Niemeyer, 2012, Postgraduate medicine.

Commentary: will it take Harry Potter to solve diabetes? Divining the future of diabetes care.

A. Moses, 2007, Journal of periodontology.

Prandial glucose regulation in the glucose triad

Lawrence A Leiter, J. Tuomilehto, R. Heine, 2004, Endocrine.

Postprandial glucose regulation and diabetic complications.

M. Hanefeld, D. Owens, J. Tuomilehto, 2004, Archives of internal medicine.

Intractable hypercalcaemia due to parathyroid hormone‐related peptide secretion by a carcinoid tumour

C. Mantzoros, L. Suva, A. Moses, 1997, Clinical endocrinology.

Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)

B. Zinman, T. Pieber, N. Poulter, 2017, Diabetologia.

Characterization of insulin-like growth factor receptors in human thyroid tissue.

A. Moses, K. Cissewski, M. Wolf, 1992, Receptor.

Imaging of the sella in the syndrome of inappropriate secretion of antidiuretic hormone

J. Kleefield, A. Moses, C. Mantzoros, 1995, Journal of internal medicine.

Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion.

M. Vance, D. Moller, A. Moses, 1989, The Journal of clinical endocrinology and metabolism.

SOMATOMEDIN‐C/INSULIN‐LIKE GROWTH FACTOR‐1 IN INFANTS WITH CONGENITAL HYPOTHYROIDISM DURING THE FIRST WEEK OF LIFE

M. Mitchell, A. Moses, R. Hermos, 1987, Clinical endocrinology.

Bromocriptine therapy in acromegaly: use in patients resistant to conventional therapy and effect on serum levels of somatomedin C.

A. Moses, R. Furlanetto, M. Molitch, 1981, The Journal of clinical endocrinology and metabolism.

Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus.

C. O'connor, J. Butler, F. Zannad, 2018, JACC. Heart failure.

Diabetes prevention: perspectives and actions of one company.

A. Moses, A. Phillips, M. Mawby, 2013, American journal of preventive medicine.

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

B. Zinman, T. Pieber, N. Poulter, 2017, The New England journal of medicine.

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

K. Almholt, D. Drucker, A. Moses, 2010, Endocrinology.

Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE

S. Heller, T. Pieber, N. Poulter, 2020, Diabetes, obesity & metabolism.

DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality

B. Zinman, S. Heller, T. Pieber, 2017, Diabetologia.

Oncogenes and growth factors in thyroid carcinogenesis.

A. Moses, A. Frauman, 1990, Endocrinology and metabolism clinics of North America.

Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)

B. Zinman, T. Pieber, Darren K Mcguire, 2019, Diabetes, obesity & metabolism.

The Relationship of Insulin-Like Growth Factor-I to Total Thyroxine in Normal and Low Birth Weight Infants

M. Mitchell, A. Moses, M. Feingold, 1989, Pediatric Research.

Comment on dried blood spot assay of IGF-I and IGFBP-3.

M. Mitchell, A. Moses, R. Hermos, 1999, The Journal of clinical endocrinology and metabolism.

Liraglutide More Effectively Achieves a Composite Endpoint for A1C, SBP and Weight Change Than Other Diabetes Therapies

S. Gough, B. Zinman, J. Buse, 2009 .

Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.

Lawrence A Leiter, B. Zinman, J. DeVries, 2013, The lancet. Diabetes & endocrinology.

Threonine for alanine substitution at position 109 of transthyretin differentially alters human transthyretin's affinity for iodothyronines.

V. Cody, J. Liepnieks, M. Benson, 1994, Endocrinology.

LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations

L. Hegedüs, B. Zinman, R. Bergenstal, 2015, Diabetes, obesity and metabolism.

Development of a hypoglycaemia risk score to identify high‐risk individuals with advanced type 2 diabetes in DEVOTE

S. Heller, T. Pieber, N. Poulter, 2020, Diabetes, obesity & metabolism.

Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes

E. Seaquist, S. Heller, J. Buse, 2019, Diabetes Care.

Effectiveness of primary care-relevant treatments for obesity in adults.

A. Moses, D. Einhorn, Y. Handelsman, 2012, Annals of internal medicine.

Recombinant Human Insulin-Like Growth Factor I Increases Insulin Sensitivity and Improves Glycemic Control in Type II Diabetes

A. Moses, D. Clemmons, L. Morrow, 1996, Diabetes.

Chicken soup revisited: Calcium content of soup increases with duration of cooking

H. Rosen, A. Moses, S. Greenspan, 1994, Calcified Tissue International.

Radioimmunoassay of somatomedin-C in filter paper discs containing dried blood.

M. Mitchell, A. Moses, R. Hermos, 1987, Clinical chemistry.